Synonyms: BCX 2600 | Diacomit ®
stiripentol is an approved drug (EMA (2007), FDA (2018))
Compound class:
Synthetic organic
Comment: Stiripentol is an orally active anti-epilepsy drug. Chemically is a mixture of enantiomers. The structure shown here does not specify stereochemistry at the chiral centres and is used to represent the mixture. Click here to view the PubChem records for associated stereoisomers.
|
|
No information available. |
Summary of Clinical Use ![]() |
May be used as an adjunct in the treatment of epilepsy. In particular, this drug is indicated for the treatment of severe myoclonic epilepsy in infancy (SMEI or Dravet's syndrome). FDA approval as a treatment for the siezures associated with Dravet's syndrome was granted in August 2018, with approval including children 2 years of age and older whose symptoms are inadequately controlled by clobazam. |
External links ![]() |
For extended ADME data see the following: European Medicines Agency (EMA) |